Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL7629511 | 0.97 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8569599 | 0.92 | FFAR3 (0.65) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8837397 | 0.92 | FFAR3 (0.65) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL10925803 | 0.92 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1545708 | 0.90 | FFAR3 (0.62) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8712901 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL5415080 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL22345882 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL9352740 | 0.88 | — | — | |
| Butyric Acid SCHEMBL27718871 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060003974-A1 | Bile acid derived steroidal dimers with amphiphilic topology having antiproliferative activity | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2006-01-05 | — | — | US | claimed |
| US-4468328-A | Purification of 12-O-tetradecanoylphorbol-13-acetate, phorbol, and 4α- | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILL. (US) | 1984-08-28 | — | — | US | claimed |
| US-4288635-A | Method for the preparation of (E)-4-bromo-2-methylbut-2-en-1-al | J. T. BAKER CHEMICAL CO. (US) | 1981-09-08 | — | — | US | claimed |
| US-11584937-B2 | Compositions and methods for controlling plant growth and development | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-21 | — | — | US | disclosed |
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2021-06-08 | — | — | US | disclosed |
| US-10532985-B2 | Heterocycle and carbocycle derivatives having TRKA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2020-01-14 | — | — | US | disclosed |
| EP-3441071-A1 | DERIVATIZED CEPHALOSPORINS | Gladius Pharmaceuticals Corporation (CA) | 2019-02-13 | — | — | EP | disclosed |
| US-10160727-B2 | Heterocycle and carbocycle derivatives having TrkA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-12-25 | — | — | US | disclosed |
| US-20180319817-A1 | Derivatized 3-Styryl-Cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-11-08 | — | — | US | disclosed |
| EP-2968352-B1 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | GLADIUS PHARMACEUTICALS CORP (CA) | 2018-09-26 | — | — | EP | disclosed |
| US-9975905-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-05-22 | — | — | US | disclosed |
| US-4075214-A | Preparation of leurosidine and novel leurosidine 4'-ethers and esters | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4066753-A | Neomycin and paromomycin derivatives | CANADIAN PATENTS AND DEVELOPMENT LIMITED (CA) | 1978-01-03 | — | — | US | disclosed |
| US-4039676-A | NEUROLEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
| US-4039551-A | 1-[(Hydroxyamino)methyl]-6-aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines | THE UPJOHN COMPANY (US) | 1977-08-02 | — | — | US | disclosed |
| US-4034040-A | Xylene-diamines as antiviral agents | PFIZER INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-4009175-A | 1-[(Aminooxy)-methyl]-6-substituted-4H-s-triazolo[4,3-a][1,4] benzodiazepines | THE UPJOHN COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-3969401-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | WILLIAM H. RORER, INC. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3968103-A | MICROBIOCIDE | ICN PHARMACEUTICALS, INC. (US) | 1976-07-06 | — | — | US | disclosed |
| US-3934008-A | PEPTIDES, HYPOCALCAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160727-B2 | Heterocycle and carbocycle derivatives having TrkA inhibitory activity | NR5A2, NPY5R, MC5R | FFAR3 538/4885HDAC3 598/4885HDAC1 369/4885 |
| US-10532985-B2 | Heterocycle and carbocycle derivatives having TRKA inhibitory activity | NR5A2, NPY5R, MC5R | FFAR3 538/4885HDAC3 598/4885HDAC1 369/4885 |
| US-20180319817-A1 | Derivatized 3-Styryl-Cephalosporins | PEPD, SI, NAALAD2 | FFAR3 4469/4885HDAC3 495/4885HDAC1 436/4885 |
| US-20060003974-A1 | Bile acid derived steroidal dimers with amphiphilic topology having antiproliferative activity | NR1H4, ABCB11, GPBAR1 | FFAR3 2368/4885HDAC3 3464/4885HDAC1 2278/4885 |
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | PEPD, SI, NAALAD2 | FFAR3 4469/4885HDAC3 495/4885HDAC1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.